150 related articles for article (PubMed ID: 24590803)
1. Essential medicines for COPD and asthma in low and middle-income countries.
Bazargani YT; de Boer A; Leufkens HG; Mantel-Teeuwisse AK
Thorax; 2014 Dec; 69(12):1149-51. PubMed ID: 24590803
[TBL] [Abstract][Full Text] [Related]
2. The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review.
Stolbrink M; Thomson H; Hadfield RM; Ozoh OB; Nantanda R; Jayasooriya S; Allwood B; Halpin DMG; Salvi S; de Oca MM; Mortimer K; Rylance S
Lancet Glob Health; 2022 Oct; 10(10):e1423-e1442. PubMed ID: 36113528
[TBL] [Abstract][Full Text] [Related]
3. Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries.
Bazargani YT; Ugurlu M; de Boer A; Leufkens HGM; Mantel-Teeuwisse AK
BMC Cardiovasc Disord; 2018 Jun; 18(1):126. PubMed ID: 29940880
[TBL] [Abstract][Full Text] [Related]
4. The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries.
Babar ZU; Lessing C; Mace C; Bissell K
Pharmacoeconomics; 2013 Nov; 31(11):1063-82. PubMed ID: 24127259
[TBL] [Abstract][Full Text] [Related]
5. Twenty-five statements on early initiation of fixed combination ICS/LABA treatment for asthma and COPD in primary and secondary care: consensus research by a modified Delphi process.
Kardos P; Bechtel B; Palovis L; Hagedorn C; Latif F
Pneumologie; 2012 Sep; 66(9):549-57. PubMed ID: 22899206
[TBL] [Abstract][Full Text] [Related]
6. An analysis of the utilisation and expenditure of medicines dispensed for the management of severe asthma.
McGowan B; Bennett K; Barry M; Owens M; O'Connor M
Ir Med J; 2009 Mar; 102(3):73-6. PubMed ID: 19489193
[TBL] [Abstract][Full Text] [Related]
7. Childhood asthma in low and middle-income countries: Where are we now?
Fischer GB; Sarria EE; Camargos P; Mocelin HT; Soto-Quiroz M; Cruz AA; Bousquet J; Zar HJ
Paediatr Respir Rev; 2019 Aug; 31():52-57. PubMed ID: 30987798
[TBL] [Abstract][Full Text] [Related]
8. [Corticosteroid treatment in airways narrowing].
Chazan R
Pneumonol Alergol Pol; 2008; 76(2):96-100. PubMed ID: 18464224
[TBL] [Abstract][Full Text] [Related]
9. Access to Cytotoxic Medicines by Children With Cancer: A Focus on Low and Middle Income Countries.
Barr R; Robertson J
Pediatr Blood Cancer; 2016 Feb; 63(2):287-91. PubMed ID: 26375626
[TBL] [Abstract][Full Text] [Related]
10. Selection of essential medicines for diabetes in low and middle income countries: a survey of 32 national essential medicines lists.
Bazargani YT; de Boer A; Leufkens HG; Mantel-Teeuwisse AK
PLoS One; 2014; 9(9):e106072. PubMed ID: 25259517
[TBL] [Abstract][Full Text] [Related]
11. Essential medicines availability is still suboptimal in many countries: a scoping review.
Mahmić-Kaknjo M; Jeličić-Kadić A; Utrobičić A; Chan K; Bero L; Marušić A
J Clin Epidemiol; 2018 Jun; 98():41-52. PubMed ID: 29452222
[TBL] [Abstract][Full Text] [Related]
12. Availability of diagnostic services and essential medicines for non-communicable respiratory diseases in African countries.
Plum C; Stolbrink M; Zurba L; Bissell K; Ozoh BO; Mortimer K
Int J Tuberc Lung Dis; 2021 Feb; 25(2):120-125. PubMed ID: 33656423
[TBL] [Abstract][Full Text] [Related]
13. Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management.
Aït-Khaled N; Enarson D; Bousquet J
Bull World Health Organ; 2001; 79(10):971-9. PubMed ID: 11693980
[TBL] [Abstract][Full Text] [Related]
14. Burden of asthma and chronic obstructive pulmonary disease and access to essential medicines in low-income and middle-income countries.
Beran D; Zar HJ; Perrin C; Menezes AM; Burney P;
Lancet Respir Med; 2015 Feb; 3(2):159-170. PubMed ID: 25680912
[TBL] [Abstract][Full Text] [Related]
15. Access to essential medicines to treat chronic respiratory disease in low-income countries.
Bissell K; Perrin C; Beran D
Int J Tuberc Lung Dis; 2016 Jun; 20(6):717-28. PubMed ID: 27155173
[TBL] [Abstract][Full Text] [Related]
16. Asthma, chronic obstructive pulmonary disease (COPD), and the overlap syndrome.
Nakawah MO; Hawkins C; Barbandi F
J Am Board Fam Med; 2013; 26(4):470-7. PubMed ID: 23833163
[TBL] [Abstract][Full Text] [Related]
17. Current and future pharmacologic therapy of exacerbations in chronic obstructive pulmonary disease and asthma.
Buhl R; Farmer SG
Proc Am Thorac Soc; 2004; 1(2):136-42. PubMed ID: 16113426
[TBL] [Abstract][Full Text] [Related]
18. Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases.
Sin DD; Man SF
Eur J Pharmacol; 2006 Mar; 533(1-3):28-35. PubMed ID: 16457807
[TBL] [Abstract][Full Text] [Related]
19. Selection of oncology medicines in low- and middle-income countries.
Bazargani YT; de Boer A; Schellens JH; Leufkens HG; Mantel-Teeuwisse AK
Ann Oncol; 2014 Jan; 25(1):270-6. PubMed ID: 24356638
[TBL] [Abstract][Full Text] [Related]
20. The risk of asthma mortality with inhaled long acting beta-agonists.
Wijesinghe M; Perrin K; Harwood M; Weatherall M; Beasley R
Postgrad Med J; 2008 Sep; 84(995):467-72. PubMed ID: 18940948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
